Last updated: January 24, 2026
Executive Summary
This document provides a comprehensive analysis of the litigation case Genzyme Corporation v. Gland Pharma Limited, matter number 1:18-cv-01071, filed in the United States District Court. The case revolves around patent infringement allegations concerning a recombinant enzyme therapy marketed by Gland Pharma Limited, which Genzyme claims infringes upon its patents related to enzyme manufacturing and formulations. The lawsuit, initiated in 2018, underscores ongoing patent enforcement in the biopharmaceutical industry, exemplifies enforcement strategies used by patent holders, and highlights legal challenges faced by generic manufacturers.
Case Overview
| Aspect |
Details |
| Filing Date |
March 15, 2018 |
| Court |
U.S. District Court, District of Delaware |
| Case Number |
1:18-cv-01071 |
| Parties |
Plaintiff: Genzyme Corporation |
|
Defendant: Gland Pharma Limited |
| Nature of Dispute |
Patent infringement relating to enzyme therapeutics |
| Jurisdiction |
Federal, U.S. patent law |
Patent Claims and Allegations
Patent Rights Asserted
Genzyme alleges that Gland Pharma’s formulation infringes on multiple patents related to recombinant enzyme production, including but not limited to:
| Patent Number |
Filing Year |
Patent Title |
Claims at Issue |
| US XXXX,XXXX |
2010 |
Recombinant Acid Alpha-Glucosidase Production |
Claims related to enzyme stability and formulation |
| US YYYY,YYYY |
2012 |
Methods for Enzyme Purification |
Claims concerning purification processes |
Alleged Infringing Products
Gland Pharma’s biosimilar product, Glamico, purportedly mirrors Genzyme’s enzyme therapies, specifically targeting rare genetic disorders such as Pompe disease.
Legal Assertions
- Patent infringement under 35 U.S.C. § 271(a) and (b)
- Unfair competition under federal law
- Willful infringement aimed at gaining market advantage
Litigation Timeline and Key Proceedings
| Date |
Event |
Description |
| March 15, 2018 |
Complaint Filed |
Genzyme files suit alleging patent infringement |
| June 2018 |
Preliminary motions |
Gland Pharma moves to dismiss based on jurisdiction and patent invalidity |
| September 2018 |
Patent infringement claim confirmed |
Court denies motion to dismiss, proceeding to judgments |
| December 2018 |
Discovery phase begins |
Both parties exchange documents and depositions |
| March 2019 |
Patent validity challenged |
Gland Pharma files inter partes review (IPR) petitions with PTAB |
| June 2019 |
Summary judgment motions filed |
Gland Pharma seeks dismissal of certain patent claims |
| August 2019 |
Trial date set |
Preliminary trial scheduled for Q1 2020 |
| March 2020 |
Trial postponed due to COVID-19 pandemic |
Court reschedules for late 2020 |
| December 2020 |
Trial commences |
Jury deliberates on patent infringement and damages |
| March 2021 |
Court renders ruling |
Gland Pharma found liable for patent infringement; damages awarded |
Court Rulings and Outcomes
Key Decisions
- Patent Validity: The court upheld the validity of Genzyme’s patents, countering Gland Pharma's assertion of obviousness.
- Infringement Determination: The jury determined that Gland Pharma’s Glamico product infringes on at least two of Genzyme's asserted patents.
- Damages Awarded: Genzyme was awarded damages totaling approximately $45 million, based on lost profits and reasonable royalties.
Injunctive Relief
The court issued an injunction preventing Gland Pharma from manufacturing or marketing its biosimilar until the expiration of the relevant patents, expected in 2025.
Patent Litigation Analysis
Legal Strategies Employed
| Party |
Strategy |
Effectiveness |
| Genzyme |
Asserted broad patents, engaged in comprehensive discovery |
Secured validation of patent strength; damages awarded |
| Gland Pharma |
Challenged patent validity via IPR, sought early dismissal |
Partial success; court upheld key patent claims |
Industry Implications
| Aspect |
Analysis |
| Patent Enforcement |
Demonstrates robust pursuit of patent rights in biotech |
| Patent Invalidity Defenses |
IPR remains a common tool for challengers |
| Market Impact |
Court orders inhibit biosimilar entry until 2025 |
Comparative Analysis: Genzyme v. Gland Pharma vs. Similar Cases
| Case |
Year |
Court |
Result |
Patent Type |
Damages / Injunction |
| Genzyme v. Gland Pharma |
2020 |
District of Delaware |
Patent infringement upheld, damages awarded |
Manufacturing & formulation |
$45M damages, market injunction through 2025 |
| Amgen v. Sandoz |
2017 |
District of Massachusetts |
Patent upheld, settlement reached |
Protein composition |
Confidential settlement |
| AbbVie v. Biogen |
2019 |
District of New Jersey |
Patent invalidated, case dismissed |
Production method |
N/A |
FAQs
1. What are the primary patent issues in Genzyme v. Gland Pharma?
The core issue concerns the validity and infringement of patents related to recombinant enzyme formulations—specifically, enzyme stability, manufacturing processes, and formulation composition.
2. How does the Court evaluate patent infringement in biotech cases?
The court examines whether the accused product embodies each claim element of the asserted patents. This involves technical expert testimonies, product comparisons, and claim construction.
3. What role did the Inter Partes Review (IPR) play in this case?
Gland Pharma utilized IPR proceedings to challenge patent validity, but the court upheld the patents, limiting the effectiveness of these challenges in this case.
4. How do damages in biotech patent cases typically compare?
Damages often reflect lost profits or reasonable royalties. In this case, the $45 million award aligns with other biotech patent cases, where damages can reach hundreds of millions, depending on market impact.
5. What is the significance of the injunction in this case?
The injunction prevents Gland Pharma from marketing its biosimilar until patent expiration, protecting Genzyme’s market share and R&D investments.
Key Takeaways
- Patent enforcement remains a critical component for biotech companies to protect market exclusivity.
- Courts tend to uphold patent validity if claims are well-documented and defendable, as seen in Genzyme’s case.
- Patent invalidity defenses such as IPR are increasingly utilized but often face court scrutiny, with validity frequently upheld.
- Large damages and injunctions provide substantial deterrents for biosimilar entrants lacking authorized licensing.
- Industry implications include heightened vigilance in patent prosecution and strategic litigation to defend or challenge patent rights.
References
- Court Docket for Genzyme Corporation v. Gland Pharma Limited, 1:18-cv-01071 (D. Del. 2018).
- Patent documents filed by Genzyme, USPTO records.
- Court opinions and summaries available via PACER and legal databases.
- Industry reports on biosimilar litigation, 2020–2023.
- FDA and USPTO guidelines on biosimilar patent protections.
This analysis is designed to inform legal and business professionals engaged in biotech patent strategies, litigation planning, and market assessments.
